
What does -prazole mean?
The -prazole stem marks a proton pump inhibitor. Why irreversible binding makes the effect outlast the drug, why dosing is before food, and the CYP2C19 trap.

Short answer: A drug ending in -floxacin is a fluoroquinolone: it inhibits DNA gyrase and topoisomerase IV, the enzymes bacteria use to manage the supercoiling of their own DNA. Blocking them is rapidly bactericidal, and the same broad reach into DNA handling is part of why this class carries safety warnings that most antibiotics do not.
Generic drug names are not invented freely. The USAN Council assigns stems so that related compounds share a family name, stating plainly that the purpose is to make prescribing safer by giving immediate recognition. The WHO INN Stem Book does the same job internationally. The stem marks the fluorinated 4-quinolones. Adding a fluorine atom to the original quinolone skeleton widened the spectrum and improved tissue penetration considerably, which is the change the stem records. It is a good example of a stem marking a generation within a family rather than the family itself.
Most antibiotics attack the cell wall or the ribosome, both structures with no close human equivalent. Fluoroquinolones attack DNA management instead. Bacterial DNA gyrase has no direct human counterpart, so selectivity is real, but human topoisomerase II is a related enzyme, and that structural proximity is part of why this class has a wider toxicity profile than a beta-lactam.
Fluoroquinolones kill faster as concentration rises, which places them alongside the aminoglycosides and against the beta-lactams, whose effectiveness depends on how long concentration stays above the minimum inhibitory concentration. The practical consequence is that a high peak matters more than continuous exposure, which is why dosing intervals in this class are longer than the half-life alone would suggest.
Quinolones chelate divalent and trivalent cations, binding calcium, magnesium, iron, zinc and aluminium in the gut to form a complex too large to be absorbed. Nothing is wrong with either substance alone; the problem is that they meet. Separating administration by a couple of hours resolves it. This is the same chemistry that causes the tetracycline interaction, so it is worth learning once for both classes.
Fluoroquinolones are associated with tendinitis and tendon rupture, most often the Achilles, and the risk rises with age, with concurrent corticosteroids and in transplant recipients. The mechanism is thought to involve effects on collagen and on tenocyte metabolism. What makes this clinically important is that rupture can occur during treatment or weeks afterwards, so stopping the drug does not immediately end the risk period.
Several fluoroquinolones delay cardiac repolarisation by blocking the rapid potassium current, lengthening the QT interval and creating the window in which torsades de pointes can begin. The risk is modest alone and compounds sharply alongside other QT-prolonging drugs, or when potassium and magnesium are low. A question pairing a quinolone with an antipsychotic or an antiarrhythmic is testing exactly this.
Regulators in several regions have narrowed recommended use after reviewing disabling and potentially long-lasting adverse effects involving tendons, muscles, joints and the nervous system. The practical position is not that these are bad antibiotics, because they are excellent ones, but that they are reserved rather than first line for uncomplicated infections where a narrower agent will do. Knowing that reasoning is more useful than memorising the list.
The members differ mainly in spectrum, which decides where each is used rather than how it works.
| Drug | Spectrum emphasis | Typical use |
|---|---|---|
| Ciprofloxacin | Strong Gram-negative, including Pseudomonas | Urinary and intra-abdominal infection |
| Levofloxacin | Broader Gram-positive and atypical cover | Respiratory infection |
| Moxifloxacin | Good anaerobic and Gram-positive cover | Respiratory, some intra-abdominal |
| Ofloxacin | Broad, including topical formulations | Ear and eye preparations |
| Norfloxacin | Narrow, urinary concentration | Urinary tract infection |
This is one of the antibiotic stems where a near neighbour means something entirely different. The -floxacin ending marks a fluoroquinolone, while -mycin and -micin mark compounds named for the organism that produced them and can belong to unrelated classes. Reading an antibiotic name carefully is a genuine skill, and exams test it because dispensing errors follow from exactly this kind of near miss.
An unfamiliar -floxacin tells you the target, that killing is concentration dependent, that absorption fails alongside any cation-containing product, that tendon and QT warnings apply, and that a narrower agent is usually preferred if one will work. That is most of a counselling answer and most of a safety answer from a single ending.
Fluoroquinolones antagonise GABA-A receptors to a degree, reducing inhibitory tone in the central nervous system. That produces headache, dizziness, insomnia and confusion at the mild end, and lowers the seizure threshold at the severe end. The risk rises in older adults, in renal impairment where the drug accumulates, and alongside non-steroidal anti-inflammatory drugs, which appear to potentiate the effect. Anyone with a seizure history is a poor candidate for this class.
This class is associated with dysglycaemia, and unusually the disturbance runs both ways. Hypoglycaemia is the more dangerous and occurs most often in older patients taking a sulfonylurea, thought to involve effects on pancreatic potassium channels similar in direction to the sulfonylurea itself. Hyperglycaemia is also described. A diabetic patient started on a quinolone therefore warrants closer glucose monitoring, which is an easily missed counselling point.
Resistance arises through point mutations in the genes encoding the target enzymes, and because a single mutation can reduce binding appreciably, it develops in a stepwise fashion under selective pressure rather than requiring a transferred resistance gene. Efflux pumps add a second route. This is part of the stewardship argument for reserving the class, since widespread use for minor infection erodes an antibiotic that is genuinely valuable for serious ones.
Studies in juvenile animals showed damage to developing cartilage, which led to longstanding caution in children, in adolescents who are still growing, and in pregnancy. Use in children is therefore restricted to situations where the benefit is clear and alternatives are unsuitable, such as certain resistant infections. The evidence of harm in humans is less definitive than the animal data implies, but the caution has held because acceptable alternatives usually exist.
The distinction between killing outright and merely halting growth places this class in context, so read our post on bactericidal versus bacteriostatic next, and the mycin versus micin post covers the naming trap directly. Dosing in renal impairment often needs creatinine clearance, and the antimicrobials practice set will test whether the class holds together.
The method below works for any generic name, which is the point of learning naming as a system rather than learning drugs one at a time. Start at the end of the word, because that is where the stem almost always sits, and read backwards until you reach something familiar. Endings are assigned; beginnings are usually the manufacturer distinguishing one compound from its siblings, so the front of the name carries far less information.
Next, ask what the stem predicts. A good stem gives you a target or a chemical family, and from either you can usually derive the main effect and the principal side effect, because most adverse effects are the intended action appearing in a tissue where it was not wanted. Then look deliberately for the exception, since every stem has one and exams are built on exactly those cases.
Finally, check rather than assume. A stem narrows the possibilities; it does not replace the label. Drugs that share a target can carry different stems if their chemistry differs, and drugs that share a stem can differ enormously in duration, which is frequently the property that decides how each is used. Treat the ending as a strong hypothesis that gets you most of the way to an answer, then confirm the detail against a primary source before it matters clinically.
It marks a fluoroquinolone, an antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV. The fluorine atom in the name records the modification that widened the spectrum of the original quinolones.
Quinolones chelate divalent and trivalent cations such as calcium, magnesium, iron and aluminium, forming a complex too large to absorb. Separating the doses by a couple of hours resolves it.
They are thought to affect collagen and tenocyte metabolism. Risk rises with age, with concurrent corticosteroids and after transplantation, and rupture can occur during treatment or weeks after it stops.
Several do, by blocking the rapid potassium current that repolarises cardiac tissue. The risk is modest alone but compounds with other QT-prolonging drugs and with low potassium or magnesium.
Regulators narrowed recommended use after reviewing disabling and potentially long-lasting effects on tendons, muscles, joints and the nervous system. They remain excellent antibiotics, but are reserved where a narrower agent will do.
Few stems carry as much safety information as this one. The ending gives you a mechanism that explains the potency, a chemical property that explains the food interaction, and a toxicity profile that explains why regulators pulled the class back from routine use. An unfamiliar -floxacin is therefore never really unfamiliar, which is the entire argument for learning drug names as a system. It is also a useful corrective to the idea that a newer or broader antibiotic is automatically a better one, because here the breadth and the warnings arrived together and for related reasons.
For study only. This article is written for learning and examination practice. It is not medical advice, not clinical decision support, and must never be used to make a decision about a real patient. Always verify against your local formulary, the product literature and a qualified pharmacist.
One mechanism explained properly every day, then brought back before you forget it.
Free to download. 7-day Pro trial. No credit card.